Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Aslan Fred, holds the title of Chief Executive Officer at Artiva Biotherapeutics, Inc..
On 2026-11-17, the insider transacted 119,771 shares.The shares were transacted at a weighted average price of $3.91 per share, resulting in a total market-relevant value of $469K.
Aslan Fred (Chief Executive Officer) sold $469K of $ARTV
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.